Hengrui Pharmaceutical (01276): SHR-1139 injection approved for clinical trials

Zhitongcaijing · 2d ago

Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”), received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for SHR-1139 injections and will conduct clinical trials in the near future.

SHR-1139 injection is a bispecific antibody independently developed by the company that targets IL-23p19 and IL-36R at the same time, blocks both pathways, and may provide more comprehensive and long-lasting inflammation control. According to inquiries, there are currently no similar drugs approved for marketing at home or abroad. Up to now, the total R&D investment for SHR-1139 injection-related projects is about 162.7 million yuan (unaudited).